Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma

Japanese Journal of Clinical Oncology

Volumn 43, Issue 1, 2013, Pages 37-44

  Suzuki, Kazuhito ^a   Terui, Yasuhito ^a   Nishimura, Noriko ^a   Mishima, Yuko ^a   Sakajiri, Sakura ^a   Yokoyama, Masahiro ^a   Takahashi, Shunji ^a   Tsuyama, Naoko ^a   Takeuchi, Kengo ^a   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Aggressive lymphoma; Anemia; C reactive protein; Lactase dehydrogenase; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; AGGRESSIVE LYMPHOMA; ANEMIA; ARTICLE; CANCER PROGNOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LOG RANK TEST; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE MEMORY; SALVAGE THERAPY;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871771939     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys194     Document Type: Article

References (40)

1. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor cell mobilization regimen for transplantationeligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17: 3776-85.
2. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-22.
3. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphomas: a 4-year follow-up study. J Clin Oncol 1994;12:1169-76.
4. Philip T, Gugielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-45.
5. Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999;17:423-9.
6. Gisselbercht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in Rituximab era. J Clin Oncol 2010;28:4184-90.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
8. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.
9. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
10. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-79.
11. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-13.
12. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-98.
13. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998;16:3264-69.
14. Blay J, Gomez F, Sebban C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92: 3562-68.
15. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-6.
16. Cheson BD, Horming SJ, Coiffeir B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-53.
17. Preti HA, Cabanillas F, Talpaz M, et al. Prognostic value of serum interleukin-6 in diffuse large-cell lymphomas. Ann Intern Med 1997;127:186-94.
18. Mahmoud FA, Riveca NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-5.
19. Perez-Encinas M, Villamayor M, Campos A, et al. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica 1998;83:752-4.
20. Jagannath S. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large cell lymphoma. J Clin Oncol 1986;4:859-65.
21. Schneider R. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980;46:139-43.
22. Swan F, Jr, Velaquez WS, Tucker S, et al. A serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7:1518-27.
23. Moullet I, Salles G, Ketterer N, et al. Freaquency and significance of anemia in non-Hdgkin's lymphoma patients. Ann Oncol 1998;9: 1109-5.
24. Zucker S. Anemia in cancer. Cancer Invest 1985;3:249-60.
25. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-4.
26. Means RT, Jr, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by g-interferon. J Cell Physiol 1992;150:59-64.
27. Johnson RA, Waddelow TA, Caro J, et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130-8.
28. Means RT, Krantz SB. Progress in understanding of the anemia of chronic disease. Blood 1992;80:1639-47.
29. Rusten LS, Jacobsen SEW. Tumour necrosis factor (TNF)-a directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 1995;85:989-96.
30. Salles G, Bienvenu J, Barbier Y, et al. Elevated levels of α-TNF and p55-R-TNF in lymphoma patients and their prognostic significance. Br J Haematol 1996;93:352-9.
31. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
32. Hagberg H, Killander A, Simmonsson B. Serum b2-microglobulin in malignant lymphoma. Cancer 1983;51:2220-5.
33. Johnson PW, Whelan J, Longhurst S, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993;67:792-7.
34. Rpdriguez J, Conde E, Gutierrez A, et al. The adjusted International Prognostic Index and β-2 microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067-74.
35. Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma based on the tumor score. Ann Oncol 1992;3:711-7.
36. Gause A, Jung W, Schmits R, et al. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkins' lymphoma. Ann Oncol 1992;3(suppl 4):49-52.
37. Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 2001;66:24-30.
38. Nakase K, Tsuji K, Tamaki S, et al. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev 2005;29:256-9.
39. Takashita T, Asao H, Ohtani K, et al. Closing of the gamma chain of the human IL-2 receptor. Science 1992;257:379-82.
40. Kitagawa J, Hara T, Tsurumi H, et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol 2009;135:53-9.